The next chapter in allogeneic CAR-T starts with data. On October 16 in New York City, we’ll share the Phase 1 readout for lasme-cel (UCART22) in r/r B-ALL and our late-stage strategy with some of the brightest minds in oncology that are shaping the future of allogeneic CAR-T.   ➡️ Stay tuned, this will be a high-signal moment.   Investor-only seating. Request an invite at: cellectis@astrpartners.com